Recent Press Releases

AAIPharma Services Announces Compendial Testing Facility ExpansionFOR

AAIPharma Services Announces Compendial Testing Facility ExpansionFOR Wilmington, N.C., March 30, 2011 - AAIPharma Services Corp., a leading provider of pharmaceutical product development and

Unilife Commences Initial Production of Unifill Prefilled Syringe

Unilife Commences Initial Production of Unifill Prefilled Syringe YORK, Pa., March 29, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (Nasdaq: UNIS; ASX: UNS) today announced

Aetna Applauds FDA Decision Maintaining Access to Affordable Medication for Pregnant Women at Risk for Premature Deliverie

HARTFORD, Conn.--(BUSINESS WIRE)-- The United States Food and Drug Administration today announced that specialty pharmacies can continue compounding 17P (hydroxyprogesterone caproate) based on a

Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe

THOUSAND OAKS, Calif., March 30, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative

Advisory to Drug Manufacturers: Formation of Glass Lamellae in Certain Injectable Drugs

[3-25-2011] The U.S. Food and Drug Administration is advising drug manufacturers of the potential formation of glass lamellae (glass fragments) in injectable drugs filled in small-volume glass

Merck: Erbitux Indication Extension Submitted for First-Line Advanced or Metastatic NSCLC in the EU

Submission is based on a new biomarker principle Merck believes that personalizing treatment is the future of cancer therapy and is committed to making this a reality Darmstadt, Germany, March 30,

AT&T Supports Project HOPE Foundation to Help Improve Quality of Maternal and Child Health Services in Indonesia

JAKARTA, Indonesia, March 30, 2011 /PRNewswire/ -- AT&T* today announced a contribution of US$25,000 (Indonesian Rupiah 219 million) to the Project HOPE Foundation to support its three-year Aceh

FDA Statement on Makena

On February 3, 2011, the U.S. Food and Drug Administration approved the drug Makena (hydroxyprogesterone caproate) for the reduction of the risk of certain preterm births in women who have had at

Pronova BioPharma reaches agreement with Apotex regarding Lovaza(TM) U.S. patent litigation

Oslo, 30 March 2011: Pronova BioPharma announced today that it has entered into an agreement with Apotex Corp. and Apotex Inc. (collectively "Apotex") to settle patent litigation regarding Apotex's

Abbott Announces Launch of Catheter-Based MitraClip® System in Australia for Mitral Regurgitation, the Most Common Heart Valve C

- First-of-its-Kind, Minimally Invasive Treatment Option for Select PatientsABBOTT PARK, Ill., March 30, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the launch of the company's

U.S. Fibromyalgia Patients Currently Taking an Approved Therapy are More Likely to Request a Discontinuation of Their Trea

EXTON, Penn.--(BUSINESS WIRE)-- Data from a recent report from BioTrends Research Group suggest that U.S. fibromyalgia patients who are currently taking one of the three agents approved for the

U.S. Health Plans Will Increasingly Look at Cardiovascular Outcomes When Determining Formulary Status of Emerging Therapie

Pharmacy Directors Report Using Incentives Other Than Tier Placement and Lack of Restrictions to Encourage Early Line Use of Generics for Dyslipidemia Treatments, According to a New Report from

Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients

THOUSAND OAKS, Calif., CAMBRIDGE, Mass. and OSAKA, Japan, March 30, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN), Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited (TSE:

Roche Introduces Next-Generation HLA Typing Solution for 454 Sequencing Systems

BRANFORD, Conn.--(BUSINESS WIRE)-- 454 Life Sciences, a Roche Company, announced today the launch and immediate availability of the new GS GType HLA Primer Sets for high- and medium-resolution

Columbia Laboratories' Provides Update on PREGNANT Study Publication

LIVINGSTON, N.J.--(BUSINESS WIRE)-- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that the Company expects results from the PREGNANT Study, a Phase III clinical trial evaluating

Presidio Pharmaceuticals, Inc. Announces Positive Results in a Phase 1b Clinical Trial of PPI-461, a Novel, Potent Broadly

SAN FRANCISCO--(BUSINESS WIRE)-- Presidio Pharmaceuticals, Inc. announced today positive preliminary results from a Phase 1b clinical trial of PPI-461, a novel HCV NS5A inhibitor for the treatment of

Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial I

PARSIPPANY, N.J. and INDIANAPOLIS, March 29, 2011 /PRNewswire/ -- Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended

Southern Research Scientists to Present New Data at the American Association for Cancer Research 102nd Annual Meeting in Orlando

BIRMINGHAM., Ala., March 29, 2011 /PRNewswire-USNewswire/ -- Southern Research Institute, a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug

MedImmune to Present 11 Abstracts on Influenza at 45th Annual National Immunization Conference

WASHINGTON, March 29, 2011 /PRNewswire/ -- MedImmune announced today it will present a total of 11 abstracts at the 45th National Immunization Conference (NIC) at the Washington Hilton in Washington,

Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective

PARIS, March 29, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the registration statement relating to the Contingent Value Rights (CVRs) offered to Genzyme